Artiva Biotherapeutics, Inc.
ARTV
$11.78
$0.564.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.12M | 4.94M | 5.26M | 4.95M | 5.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.43M | 21.93M | 22.90M | 22.81M | 22.17M |
| Operating Income | -24.43M | -21.93M | -22.90M | -22.81M | -22.17M |
| Income Before Tax | -23.52M | -20.77M | -21.53M | -21.25M | -20.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.52M | -20.77M | -21.53M | -21.25M | -20.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.52M | -20.77M | -21.53M | -21.25M | -20.31M |
| EBIT | -24.43M | -21.93M | -22.90M | -22.81M | -22.17M |
| EBITDA | -23.76M | -21.27M | -22.24M | -22.17M | -21.54M |
| EPS Basic | -0.95 | -0.85 | -0.88 | -0.87 | -0.83 |
| Normalized Basic EPS | -0.60 | -0.58 | -0.55 | -0.54 | -0.52 |
| EPS Diluted | -0.95 | -0.85 | -0.88 | -0.87 | -0.83 |
| Normalized Diluted EPS | -0.60 | -0.58 | -0.55 | -0.54 | -0.52 |
| Average Basic Shares Outstanding | 24.68M | 24.57M | 24.48M | 24.38M | 24.34M |
| Average Diluted Shares Outstanding | 24.68M | 24.57M | 24.48M | 24.38M | 24.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |